Revolution Medicines Surges on Unprecedented Cancer Trial Data
Revolution Medicines shares jumped sharply after clinical trial results for its cancer therapy were characterized as unprecedented. The data point carries outsized weight because RAS-targeted oncology is a historically resistant space where efficacy breakthroughs drive significant pipeline revaluation. Investor attenti